Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Amalgamation

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Apr 30, 2021 1:44am

146 Views

Post# 33099471

RE:RE:RE:RE:RE:RE:RE:Amalgamation

The other 2 lawyers represent JLW and Dan

3burtc wrote: Both companies with purchases at $5.22 is more than a coincidence and they can call them whatever they want. Dan said at Bloom and burton that they have 4 sets of lawyers working on amalgamation. Okay you have Antibe, AH, and who do the other 2 represent?

<< Previous

Bullboard Posts

Next >>

Full Circle Lithium goes global with its battery fire-fighter